San Diego, California -- Biotechnology company CoDa Therapeutics has received $754,000 in new venture capital debt financing, according to an SEC regulatory filing.
CoDa says that it is focused on "the development and commercialization of wound care therapeutics based on gap junction modulation."
Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.
A total of two investors participated in the offering.
CoDa is still seeking $1.7 million in additional debt investment, according to the filing.